Business Context and Reporting Period
Company: Virax Biolabs Group Ltd
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: March 2023 (Event date: March 8, 2023; Closing date: March 10, 2023)
Principal Executive Offices: London, United Kingdom
This filing reports the entry into a Material Agreement and an unregistered sale of equity securities via a private placement offering.
Key Financial Metrics and Transaction Details
Capital Raised: Approximately $4,000,000 in gross proceeds (before fees and expenses).
Securities Issued:
- Ordinary Shares: 1,500,000 shares at $1.04077 per share.
- Pre-Funded Warrants: 2,343,309 warrants at $1.04067 per warrant (issued to prevent beneficial ownership exceeding 4.99%).
- Series A Preferred Investment Options: Up to 3,497,412 shares.
- Series B Preferred Investment Options: Up to 3,843,309 shares.
- Placement Agent Warrants: 269,032 warrants issued to H.C. Wainwright & Co. at an exercise price of $1.3010 per share.
Exercise Terms: Preferred Options have an exercise price of $0.80202 per share and are exercisable immediately for 5.5 years. Pre-Funded Warrants do not expire.
Financial Performance: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics for the period.
Material Changes and Unusual Items
Warrant Cancellation: Simultaneously with the closing of this offering, the Company cancelled previously issued warrants to purchase 3,495,000 Ordinary Shares (issued in November 2022) which had an exercise price of $1.73 per share.
Beneficial Ownership Limitations: The transaction includes provisions limiting beneficial ownership to 4.99% (adjustable up to 9.99% with 60 days' notice) to prevent the purchaser from exceeding regulatory thresholds.
Registration Rights: The Company entered into a Registration Rights Agreement to file a Registration Statement covering the resale of the securities.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses on the mechanics of the capital raise and does not provide specific operational guidance or financial outlook.
Risks and Contingencies:
- Registration Status: Securities sold pursuant to Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. Ordinary Shares issuable upon exercise are not registered and cannot be sold in the U.S. without an effective registration statement or exemption.
- Cashless Exercise: Pre-Funded Warrants and Preferred Options may be exercised on a cashless basis if no effective registration statement is available at the time of exercise.
- Legal Disclaimer: The report does not constitute an offer to sell securities in any state where such offer would be unlawful.
Investor Verification Checklist
- Verify the net proceeds after deducting placement agent fees and offering expenses.
- Confirm the dilution impact of the 1,500,000 ordinary shares and the potential issuance of up to 7,340,721 shares via Preferred Options.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification obligations.
- Monitor the status of the Registration Statement filing required under the Registration Rights Agreement.
- Assess the impact of cancelling the 3,495,000 warrants with the higher $1.73 exercise price on future capital structure.